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Background: The human leukocyte antigen (HLA) region has shown to have the strongest 
disease associations and recent studies have shown that expression levels of these HLA molecules 
play a major role in the clinical course of diseases.  Differences in the expression levels of these 
molecules have been found to have a major effect on their ability to present specific peptide 
antigens. HLA molecules are critical to the interaction between diseases and components of the 
immune system.   Expression of such molecules, namely HLA-C and HLA-A, have been shown 
to associate with HIV disease outcomes. An increase in expression of HLA-C leads to protection 
against HIV whereas an increase in HLA-A expression leads to rapid HIV progression. 
Furthermore, studies have shown the region with the strongest genetic effect falls within the HLA-
B gene, as determined by genome wide association studies.  However, limited information is 
available for HLA-B allelic expression levels and the variation across differential cell types.   
Materials and Methods: Allelic expression levels of HLA-B were measured using 
cryopreserved PBMC samples from HIV negative and positive cohorts with HLA typing.  
Antibodies specific to the HLA-B protein were identified. The affinity of the antibodies relative 
to class-I alleles were determined. Based on these affinities, donors with specific alleles were 
selected for HLA-B cell surface measurement using the flow cytometer. mRNA levels were 
measured across HLA-A, -B, -C and -E genes within the following cell types T-cells, B-cells, 
Monocytes and NK cells. These levels and a comparison of HIV infected and uninfected mRNA 
levels from the same donor were measured using droplet digital PCR (ddPCR).  
Conclusions: Contrary to HLA-B mRNA expression levels, we find cell surface expression levels 
vary in an allele-specific manner. We further observed differential mRNA expression patterns for 
HLA-A, HLA-B, HLA-C and HLA-E across cell types.  We also observed no mRNA expression 
variation across pre- and post- HIV samples. When comparing HLA-B mRNA and surface 
expression across alleles and donors no significant correlation was found. However, at an donor 




knowledge and fills in some of the gaps in knowledge surrounding HLA-B expression.  We also 
report, for the first-time, variation in allele specific expression, variation in expression across 







Chapter one: Introduction  
“Human leukocyte antigen (HLA) region, located within the Major histocompatibility 
complex (MHC), is the most polymorphic region of the human genome and comprises of just 
over 14,800 HLA-I alleles1.  Since the discovery of the HLA molecules over five decades ago, 
the HLA research platform has explosively developed into a remarkable field making the HLA 
complex fundamental in basic and clinical immunology.  HLA’s have been recognized as a major 
predictor in the extremes of disease outcome and have been reported as being one of the two loci 
responsible for modifying Human Immunodeficiency Virus (HIV) disease2. 
 
The precise mechanism of HLA molecules governing protection against diseases is still 
a major gap in research.  However, it has been speculated that the precise mechanism underlying 
the protective effects of HLA-I molecules may vary from one to another3 yet the underlying 
effects of these class-I molecules are not completely understood4 and is continuously being 
investigated.  Possible mechanisms governing the transcriptional regulation of HLA-I gene 
expression have been discussed, however emphasis that a better comprehension of this highly 
regulated expression is required in order to consider therapeutic approaches aimed at modulating 
the level of HLA expression level5.  Expression of these molecules are critical in transforming 
our understanding of host genetics, its application in disease modification and control and 
evolution2,5. 
 
Several genome wide association studies (GWAS) have been conducted with the aim of 
identifying host factors that contributed to HIV and other disease outcomes.  The results of these 
studies indicate the human leukocyte antigen class-I genes exhibit the strongest associations 
supporting previous studies that have targeted the HLA genes6–8.  The influence of variability in 





well appreciated.  The most clearly defined escape mutations arise within CD8 T cell epitopes 
recognized by HLA-B alleles that are linked with successful control of HIV9.  Allelic 
polymorphisms that influence differential antigen presentation and HIV disease outcomes have 
been extensively studied for HLA-B alleles10,11.  However, despite HLA-B being widely studied 
not much is known about the allelic-specific expression levels. 
 
This study, therefore, focused on measuring the allelic expression levels of HLA-I 
molecules, particularly HLA-B, and bridging the gaps in knowledge surrounding HLA-B 






Chapter Two: Literature Review 
2.1 The Human Leukocyte Antigen Region 
2.1.1 Location, Structure and Function of HLA-I 
”HLA is the human version of the Major Histocompatibility Complex and is located on 
chromosome six of the genome (figure 1).  The HLA region is comprised of three classes with 
the class-I region consisting of the three classic human leukocyte antigen (HLA) gene loci: HLA-
A, HLA-B, and HLA-C; three non-classic HLA-E, HLA-F, and HLA-G, which show limited 
polymorphism compared to the classic class-I; and other related non-coding genes and 
pseudogenes.  These molecules are fundamental to the development of innate and adaptive 













Figure 1: HLA Complex. Location of the HLA region on chromosome 6.  Human 
chromosome 6 with amplification of the HLA region.  Specific HLA-I B, C, and A alleles and the 







These complexes are located on the short arm (p) of chromosome 6 and are composed of 
252 genes in close approximation of each other13.  The HLA class-I genes are a heterodimer, 
consisting of a heavy alpha chain and a light beta chain (beta-2 micro-globulin) of approximately 
12 kDa in size.  The heavy alpha chain is anchored in the membrane and gives rise to its 
transmembrane characteristic.  
The heavy alpha chain is approximately 45 kDa in size and its gene contains 8 exons5,14.  
Exon 1 encodes the leader peptide, exon 2 and 3 encode the alpha1 and alpha2 domains, which 
both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane 
region and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 
are responsible for the peptide binding specificity of each class one molecule (figure 2).   
These classical transmembrane HLA-I molecules are genetically inherited making them 
important host genetic risk factor in infectious disease that are expressed on the surfaces of most 
of the human nucleated cells15.  Molecules encoded by the HLA region are involved in a multitude 
of functionalities such as: antigen presentation, inflammation regulation, the complement system, 
and the innate and adaptive immune responses, indicating the HLA’s importance in immune-
mediated, autoimmune, and infectious diseases16.  In antigen presentation, the HLA molecules to 
bind to antigens derived from pathogens and display them on the cell surface for recognition by 
the appropriate cells CD8+ T-cells, which then kill the antigen-presenting cells (APCs)17.    
A defining feature of the HLA-I molecules are their tremendous polymorphism which is 
concentrated in the regions of the HLA molecule involved in peptide binding14.  These 
polymorphisms influence the specificities of the peptide binding in the assembled HLA-I proteins 
to allow for the presentation of a distinct and diverse pool of antigenic peptides by each HLA-I 
molecule18.  In principle, a single HLA molecule may bind to more than a million different 
peptides19,20.  It was proposed that infectious diseases drive HLA-I polymorphism due to the 











(b)   
   
 
Figure 2: a) Typical transmembrane HLA-I molecular structure highlighting the heavy 
alpha chain and light beta-2-microglobulin complex.  b) Coding region of the heavy alpha chain 
exons 1 to 822. 
 
2.1.2 Disease Association 
Being the richest segment in the human genome, the HLA region is associated with 
several diseases of various sources, such as bacterial, viral, inflammatory, cancer, neurologic 
disorders, and drug hypersensitivity23.  MHC and autoimmune diseases have been associated 
since the early 1970s and were some of the earliest described genetic associations that have 
remained as the strongest risk factors for autoimmune diseases24,25.   Allelic variations in the HLA-
I molecules are known to have implications in susceptibility to infectious diseases, autoimmune 
conditions and malignancies5.     
It was reported that associations within the HLA-I locus suggest that CD8+ T-cell 
responses play a critical role in major viral infections such as HIV, dengue, and Hepatitis C 
(HCV)26.  Slower HIV disease progression was attributed to the increase of CD8+ T-cell 
responses in infected donors, specific to conserved HIV proteins such as Gap p24 antigens 





severe dengue disease with HLA-I due to weaker CD8+ T cells responses27.   In HCV, HLA-B*27 
presents the most conserved epitopes of HCV and elicits strong cytotoxic T-cell responses, thus 
reducing the ability of HCV to escape from host immune responses28.  Table 1 highlights some 
of these and other major HLA disease associations that have been discovered over the decades.   
Table 1: Categorized Summation of Major HLA Disease Associations  










Type 1 diabetes 
Systemic lupus erythematosus 
Viral13,14,23,24,27–36 
Human immunodeficiency Virus (HIV) 
Hepatitis B Virus (HBV) 
Dengue hemorrhagic fever (DHF)/Dengue shock 
syndrome (DSS 
Hepatitis C Virus 
Adenovirus 
Coxsackie Virus Type II 
Parvovirus 
Herpes Simplex Virus 
Bacterial37–39 





Acute Anterior uveitis 
Parasitic38 Malaria 
Schistosomiasis 







We have also found that several HLA molecules that have shown to associate with 
diseases in conferring protection, have found to increase the risk or susceptibility to another 
disease.   Due to our continuously evolving immune system, in relation to exposure to various 
infectious diseases, HLA molecules have thus adapted and evolved resulting in a variety of 
peptides being presented on the cell surface.  The continuous evolution of HLA molecules gives 
rise to the number of alleles / HLA forms increasing at a rapid rate.  However, having said this, 
infectious disease continues evolving and adapting as well.  Rock et al., 2016 illustrated that some 
alleles present highly specific peptides at the cell surface and this specificity results in the reason 
as to why some alleles illicit a greater immune response to a particular disease than others40.  This 
association directly links HLA molecules with diseases and their outcomes.  The peptides that are 
presented by HLA-I molecules and the polymorphisms that exist have been shown to contribute 
to differences in disease outcome41.  In addition to presenting peptides on the cell surfaces, HLA 
expression was found to also associate with diseases outcomes. 
2.2 HLA Expression 
2.2.1 HLA Expression and disease association 
Over the past few years, a few studies have explored the expression of HLA and the 
association with several diseases34,35,42,43. It was observed that expression levels have a direct 
association with disease outcomes and vary at the allele level, that is most HLA genes show allele 
specific expression variation4–6,14,18,23,34–36,42–48.  This variability in allelic-expression has shown to 
be important in HIV infection, Crohn’s disease, Hepatitis B Virus (HBV) clearance, graft-versus-
host disease (GVHD) after unrelated hematopoietic cell transplantation, Parkinson’s disease, 
systemic lupus erythematosus and certain cancers23,36,43,49. Therefore, varied expression levels for 
a single gene within the HLA region could affect multiple disease outcomes. This was illustrated 
within the HLA-C locus where variation in expression was shown to associate with diseases HIV, 





Expression levels of HLA molecules have an important influence on their function.   It 
has been implicated that the nature of the HLA–viral peptide interaction is a major factor 
modulating durable control of the HIV infection42.  The expression levels, however, of HLA-A 
and HLA-C were shown to associate with HIV disease in opposing ways14,34,35,42. Increased 
expression of HLA-C associated with decreased HIV disease progression, however, elevated 
expression of HLA-A associated with loss of HIV control. These genes were shown to work 
independently of each other. Higher expression of HLA-C correlated with increased cytotoxic 
responses and are also conferred greater immune pressure on HIV35,42. Elevated expression of 
HLA-A contributes significantly to level of HLA-E expression, which promotes inhibition of 
Natural Killer (NK) cells and subsequently leads to diminished NK cell killing of HIV infected 
target cells35.  Currently, there is no supporting literature that is available for HLA-B expression 
in association with HIV disease outcomes.   
In addition to disease associations, Ramsuran et al., 2017 observed that irrespective of 
the similarity between the promoter sequence within the HLA-I loci, there was poor correlation 
in expression levels and promoter regions as well as in expression across HLA-A, HLA-B and 
HLA-C.  This was indicative that the classical class-I genes are regulated independently of each 
other, consequently by mechanisms not completely understood yet23.   
2.2.2 HLA-B 
2.2.2.1 HLA-B Expression 
Allelic variation of gene expression is common in humans and is of interest because of 
its potential contribution to variation in heritable traits.  A decrease in expression may sometimes 
result in an increase in risk of disease susceptibility; and the extent of the risk is co-dependent on 
the variation in expression across donors.   
The HLA-B gene has many different normal variations called alleles, allowing donor 





known, and closely related alleles are categorized together. Several variations of HLA-B genes 
appear to play a role in the progression of HIV infection to acquired immunodeficiency syndrome 
(AIDS).  HLA-B*5701 has been associated with an extreme sensitivity to abacavir – drug used 
in the treatment of HIV-1 and slows he spread of HIV within the body. Previous studies have 
suggested that HIV positive donors who possess the HLA-B27 or HLA-B57 genes, tend to 
progress at a slower rate to AIDS. Whereas other researchers have observed the converse in HIV 
positive donors who have the HLA-B35 gene45. The mechanism by which HLA influences disease 
progression is not completely understood. It has been suggested that specific HLA molecules 
maybe directly involved in restricting HIV replication however this process is not fully 
understood.  
Genetic makeup of a person’s HLA affects the rate of HIV disease progression. Sites in 
HLA-B within the MHC have been reported to be highly associated with HIV control45.  A recent 
study had explored this variation across alleles and found that the variation in expression across 
HLA-A and HLA-C alleles vary in an allele specific manner, whereas the expression across HLA-
B alleles does not display a similar trend in allele specific variation (figure 3)23,36,42.  In fact, the 
expression variation across various alleles were found to be relatively low and remained 
consistent throughout (figure 3b).  Unlike HLA-A and HLA-C, HLA-B shows a much higher 
nucleotide diversity upstream of the transcription start site (TSS), therefore it is surprising that 








































Figure 3: Differential expression of a) HLA-A36, b) HLA-B23 and c) HLA-C42 across alleles 
– plotted in ascending order.  Relative expression is plotted twice for each donor for their 





relative mRNA allelic expression whilst c) denotes cell surface expression of HLA-C alleles.  In 
a) red dots denote linear regression estimates, green dots denote homozygous donors and 
horizontal lines denote average allelic expression; whereas in b) horizontal line denotes the 
estimated HLA-B expression levels for each lineage as calculated using linear regression; c) red 
dot denotes the homozygous donors. 
 
These findings substantiate that there is no correlation between promoter sequence 
diversity and expression at the mRNA level and further differentiates HLA-B from HLA-A and 
HLA-C.   Interestingly, this was the only study that reported HLA-B allele specific mRNA 
expression using peripheral blood mononuclear cells (PBMC)23.  These cells are composed 
collectively of lymphocytes (approximately 70 – 85 %) and monocytes (approximately 10 to 30 
%) and current literature does not report the expression of HLA across cell types.  It would be 
interesting if some cell types had higher expression than others.  Such data would further validate 
the presence of alternate mechanisms that may be responsible for the variation in expression or 
with the nucleotide diversity observed in the promoter region of HLA-B as previously described23. 
Kiepiela, et al., 2004 stated that the variation in viral set-point was strongly associated 
with HLA-B, but not HLA-A, allele expression. It was also observed that greater selection 
pressure is imposed on HIV-1 by HLA-B alleles than by HLA-A3. This substantiates that the 
principal focus of HIV-specific activity is at the HLA-B locus. Furthermore, HLA-B gene 
frequencies in the population are those likely to be most influenced by HIV disease, consistent 
with the observation that B-alleles evolve more rapidly than A alleles. The dominant involvement 
of HLA-B in influencing HIV disease outcome is of specific relevance to the direction of HIV 
research3.  HLA-B alleles have also been reported to pose better protective activity against HIV-
1 than HLA-A alleles possibly due to differences in in HLA-restricted HIV-1-specific CD8+ 
cytotoxic T lymphocyte function, however the exact mechanism is unknown3,50. Expression levels 
of HLA molecules have an important influence on their function14,45. It is therefore pivotal to gain 






Gene expression levels are believed to be crucial in the involvement of the HLA complex 
in the pathogenesis of particular diseases5.  Studies have also revealed that HIV protein, Negative 
Regulatory Factor (Nef), downregulates HLA-A and HLA-B types at the cell surface however 
with different efficiencies50,51.  HLA-B is known to be more protective against HIV-1 and was 
also observed to exhibit a greater resistance to downregulation by Nef in comparison to HLA-A 
types3,50–52.  This exploitation by HIV highlights the importance of HLA-I expression in 
modulating HIV disease progression.  
  Apps et al., 2015 showed that in HIV infected cells, HLA-A expression was 1 to 3 times 
higher and HLA-B was 2 to 5 times higher than HLA-C.  HLA-C expression was not modified 
by Nef.  HLA-A and HLA-B downregulation was approximately 4 times lower in HIV infected 
cells post infection14.  To date, there is no comparative information on the difference in expression 
at the mRNA level pre and post HIV infection.  It would be of interest to explore these sectors 
and build fundamental insight into the most polymorphic region within the human genome.  
Extensively studied HLA alleles, HLA-B*57 and B*27, have been proven to illicit protective 
properties against HIV-1 disease whilst HLA-B*35 is predisposing to the disease.  To date, HLA-
B has been known to have the strongest disease association as well as being the most polymorphic 
loci in the human genome, yet limited information is available with regard to the allelic expression 
of HLA-B at the mRNA and cell surface levels6–8,53.    
 
2.2.2.2 Measurement of HLA-B expression 
Some alleles offer a better immune response than others and this may be attributed to the 
varying levels of expression observed40.  However, as reported in previous studies, the variable 
expression may offer contrasting responses.  We have observed that high surface expression of 






At the cell surface using specific haplotypes (A*02:01, B*44:02, C*05:01), HLA-B 
protein expression level were found to be similar to HLA-A, however 13 to 18 times higher than 
HLA-C using flowcytometry as a quantification method and 4 to 5 times higher than HLA-C 
when mass spectrometry was used as a quantification method14.  Further to this, HLA-E 
expression was found to be 25 times lower than HLA-C surface expression using mass 
spectrometry14.  This discrepancy using the two technologies may be attributed to the variation in 
protein conformation or perhaps the location of the protein measured14.   
While expression level has significant consequences for HLA function, HLA-B allele 
specific expression is not well established at the cell surface.  Every donor can express six HLA 
alleles, two for each of the classical class-I HLAs, that is, HLA-A, HLA-B and HLA-C, with 
exception of HLA-E.  Due to the high level of polymorphism that exists in the HLA loci and 
therefore the HLA-B loci, precise quantification is very challenging.  Currently, the two methods 
in use are flowcytometry and mass spectrometry, as discussed above.  However, due to 
availability or lack thereof, it is difficult to identify a suitable antibody that can be used across all 
alleles with equal affinity. 
Unlike HLA-C, that uses the DT9 antibody to measure all HLA-C alleles with equal 
affinity, within the HLA-B locus there is no single monoclonal antibody with the ability to 
measure expression levels across all common HLA-B alleles34. It is therefore difficult to 
determine the expression across several HLA-B alleles for comparison. challenging.  
Commercially, there are several antibodies that are specific to molecules from each locus, 
however their binding cannot merely be compared because of the differences in affinity for their 
respective antigens. This illustrates that a single antibody cannot be used to measure a broad range 
of alleles for HLA-B as the affinity variation, which is defined as the strength to which an antibody 
binds to an antigen, is too broad and therefore expression levels measured thereafter are not 
comparable across alleles.  Also, some antibodies can bind to a broad range of alleles across the 





alleles from HLA-I.  These were common hindsight’s in several expression experiments 
previously performed and discussed42,54,55.   
In order to overcome such observations, specific antibodies were required to be screened 
such that each antibody will only detect a subset of alleles with equal affinity within a large cohort.  
Apps et al., 2009 used a fluorescence bead based method that incorporated commercially 
available beads each coated with donor coated HLA purified from transfected 721 221 cells56.  
The LABScreen single antigen-bead (LSA) based assay, from Onelambda, allows for a precise 
determination of antibody profiles against HLA’s (figure 4).  The LSA is designed to screen HLA-
I antibodies that are reactive to one or more dominant epitopes providing a comprehensive assay 
to evaluate antigens found frequently in the population.  Using the LSA beads and the Luminex 
assay, a range of anti-Bw4 antibodies can be used screened in order  to determine the affinity 
against 100 class-I HLA alleles, inclusive of 4 control beads.   The affinities for specific alleles 










Figure 4: LABScreen Single Antigen assays leverage Luminex® bead-based multiplexing 





mRNA expression allows researchers to determine if a gene of interest (GOI) is 
expression at high or low levels, if expressed at all.  This expression results the functional 
capability of the protein synthesised.  The most sensitive method used for detection and 
quantification of mRNA expression exists in PCR (RT-qPCR and ddPCR).  Digital PCR (dPCR) 
enables precise, highly sensitive quantification of nucleic acids. Traditional PCR is an end-point 
analysis that is semi-quantitative because the amplified product is detected by agarose gel 
electrophoresis. Real-time PCR (or qPCR) uses fluorescence-based detection to allow the 
measurement of accumulated amplified product as the reaction progresses. qPCR requires 
normalization to controls (either to a reference or to a standard curve), allowing only relative 











Figure 5: Schematic illustration of Droplet digital PCR (ddPCR) reaction. Sample is 
partitioned into ~20,000 droplets, followed by amplification.  Thereafter droplets containing 
target sequence are detected by fluorescence and scored as positive, and droplets without 
fluorescence are scored as negative. Poisson statistical analysis of the numbers of positive and 





Digital PCR is a technique that combines traditional PCR amplification and fluorescent-
probe–based detection methods to provide highly sensitive absolute quantification of nucleic 
acids without the need for standard curves58,59.  Due to the similarity across the classical class-I 
genes, and the extreme of polymorphisms that exist within exons 2 and 3, primer efficiency and 
specificity is crucial in any qPCR mRNA allele lineage assay.    
In this study, we use droplet digital PCR (ddPCR) which, as described above, is a method 
for performing absolute quantification of a product.   This procedure is based on water-oil 
emulsion droplet technology where the sample was fractionated into 20 000 droplets, and PCR 
amplification of the specified molecules occurred in each donor droplet (figure 5).  Samples are 
amplified using a thermocycler, and droplets from each sample are analysed using the QX100 
Droplet Reader, purchased from Biorad.  Using florescent detection, PCR-positive and PCR-
negative droplets are counted to provide absolute quantification of the target DNA in digital form.   
A study published in human molecular genetics looked at HLA-A and measured the allelic 
expression in healthy European donors using qPCR36.  Each donor was plotted twice for their 
respective HLA-A allele and the illustrated findings revealed a gradient in mRNA allelic 
expression.   The variation in expression was attributed to epigenetic factors, namely DNA 
methylation, that resulted in the gradient of expression across HLA-A alleles36.  This observation 
was quite distinct in HLA-A for transcriptional regulation in comparison HLA-B and HLA-C, 
which was surprising since the CpG target sites across HLA-A, HLA-B and HLA-C are similar yet 
HLA-B and -C remain unmethylated36.  
 mRNA expression provides valuable information from a pre-transcriptional level and 
provides insight on regulatory pathways that may contribute to disease outcomes.  Several such 
studies explored different contributory mechanisms, regulatory factors and single nucleotide 
polymorphisms that have been linked to a variety of disease associations and outcomes34–36.  The 





A, HLA-B and HLA-C are not completely understood.  This is an area that receiving much 
attention in disease associations. 
 
2.3 Research Project Overview 
2.3.1 Rationale for the study: 
Genome wide association studies (GWAS) have shown the HLA-I genes exhibit the 
strongest associations with HIV disease outcomes. The region showing the strongest genome-
wide association falls within the HLA-B gene region.  Recent studies have shown expression 
levels of HLA-A and HLA-C are associated with HIV disease outcomes. An increase in 
expression of HLA-C leads to delayed progression against HIV whereas an increase in HLA-A 
leads to rapid HIV disease progression.  
Limited information is available for the allelic expression levels for HLA-B gene. 
Analysis of HLA-B expression level is likely to be important not only in HIV infection, but also 
other infectious diseases and immune-related disorders in which HLA-B has previously been 
shown to play a role. Measuring HLA expression levels adds another dimension to the extreme 
diversity of HLA-I molecules that accounts for variability in immune responses across donors and 
may suggest possible drug targets to modulate host responses to infections. Despite HLA-B being 
widely studied, not much was known about the allelic expression levels, variation of expression 
across differential cell types and HIV downregulation of HLA-I at the mRNA level. 
 
2.3.2 Study Aims and Objectives 
This study explores the HLA-B allelic surface expression variation and to further determine HLA-
B expression variation across several cell types such as T cells, B cells, Monocytes, and NK cells. 





• Objective 1: Determine HLA-B differential allele-specific expression levels on the cell 
surface using flow cytometry 
• Objective 2: Assess HLA-A, -B, -C and -E mRNA expression levels across T-cells, B-
cells, monocytes and natural killer (NK) cells using digital droplet PCR (ddPCR) 
• Objective 3: Assess the effect of HIV on HLA-class-I types at the mRNA level  
 
This study aimed to examine these gaps in knowledge and reports for the first-time 
variation in allele specific expression, variation in expression across differential cell types as well 






Chapter three: Materials and Methods 
3.1 Study Ethics Consideration  
Ethical approval for this study was obtained from the Biomedical Research Ethics 
Committee (BREC). The BREC approval number was BE539/17.  Ethics approval for use of 
samples previously obtained from the HIV negative and positive study cohorts that have had HLA 
typing successfully concluded, were referenced on the BREC application.  This study was 
conducted within good clinical practice ethical guidelines. (See Appendix A) 
3.2 Study Samples  
HIV infected, and uninfected samples used in this study were obtained from the Centre 
for AIDS Program of Research (CAPRISA).   All samples that were considered for analysis have 
been previously HLA typed.  All samples were stored at -80 °C until required for analysis. 
3.2.1 CAPRISA 002 cohort 
The CAPRISA 002 cohort is an Acute Infection Study that was established between August 2004 
and May 2005.  The cohort consists of high-risk HIV-uninfected women, working as female sex 
workers in and around a large urban area.  CAPRISA 002 is the first acute longitudinal study in 
South Africa that reports acute infection in a prospective cohort of HIV-1 subtype C infection60.  
Details of the establishment of this study cohort was published by Loggerenberg et al., 200860.  
The aim of the CAPRISA 002 study was to identify host and viral factors during the acute and 
early phases of HIV-1 infection that may have a significant impact on the subsequent course of 
the disease.   
3.3 HLA Expression 
3.3.1 RNA extraction 
RNA extraction was performed on PBMC’s and sorted cell types followed by cDNA 





used to measure cell surface expression of HLA-B and mRNA expression of HLA-A, HLA-B, 
HLA-C and HLA-E.  HIV positive (HIV+) samples were used in conjunction with the 
corresponding HIV- samples for pre- and post-HIV infection mRNA expression comparison 
study.  
3.3.2 Cell surface expression 
3.3.2.1 Antibody affinity screening 
Using the Luminex assay with LABScreen single antigen-beads (LSA) purchased from 
one lambda, we screened two commercially available antibodies, REA274 and 22E1, against 96 
HLA-I alleles, as per previously described34,56.  Each of the one hundred alleles tested were 
attached to different size polystyrene bead.  Briefly, the beads were incubated with unlabelled 
primary or isotype control mAb for 30 min at room temperature, washed five times and labelled 
with monoclonal FITC-conjugated antibody to murine IgG or IgM (Sigma-Aldrich).  The FITC-
conjugated mAb labelling were analysed using a Luminex 100 reader.  Results shown are median 
fluorescence intensities (MFI) of a minimum of 100 events for each HLA-I-coated bead.  
(Miltenyi Biotec).    
3.3.2.2 Allele Selection 
HLA-B alleles were selected based on the affinities against each antibody. Allele within 
a 10% affinity variability were selected for comparison. Therefore, each antibody will only 
detect a subset of alleles with similar affinity.  Donors with a selected allele, based on the 
affinities, were used to compare HLA-B allelic expression levels. Donors were carefully 
examined to ensure other HLA-I alleles were not detected by the antibody.  
3.3.2.3 Flowcytometry 
CD3+ T-cells were centrifuged at 300 xg for 10 min and washed with wash buffer. 





and incubated for 10 minutes. Sampled were washed using wash buffer and centrifuged at 300 xg 
for 10 min. Cell pellet was resuspend in a suitable amount of buffer for analysis by flow cytometry 
using the BD LSRFortessa.  A combination of gating strategies was applied to distinguish our 
cells of interest – CD3+ T-cells.  A Bw6 allele was selected from the cohort of samples and used 
as negative control with each set of antibody specific allele subset.  All data generated from flow 
cytometry were analysed using flowjo software (version 10.5.2). All plotted graphs and statistical 
analysis were performed using GraphPad Prism version 5.0.  HLA-B allelic expression levels was 
reported as (MFI).   
3.3.3 mRNA Expression 
3.3.3.1 Cell sorting 
Seven homozygous donor samples were selected and sorted using Fluorescence-activated 
cell sorting (FACS), PBMC samples were sorted into the following cell types: T-cells, B-cells, 
Monocytes and NK cells.  All sorted cells were stored at -80 °C for further analysis.   
3.3.3.2 RNA extraction and cDNA synthesis 
As mentioned in section 3.3.1, RNA was extracted for the sorted cells types: T-cell, B-
cells, Monocytes and NK cells.   cDNA synthesis was performed using the cDNA two step 
synthesis kit purchased from Bio-Rad.  Synthesised samples were stored at -80 °C for further 
analysis. 
3.3.3.3 Effect of HIV on HLA-I mRNA Expression 
Two donors were selected to assess the effect of HIV pre- and post- infection on HLA-I 
expression.  HIV- and HIV+ PBMC samples were used to extract RNA, thereafter synthesising 
cDNA for analysis by ddPCR as described in 3.3.1 and 3.3.3.4, respectively.  ddPCR was used to 
measure the expression of HLA-A, HLA-B, HLA-C and HLA-E pre- and post- HIV infection.  






3.3.3.4 Droplet Digital PCR (ddPCR)  
In this study, ddPCR was used to quantify the expression levels of HLA-A, HLA-B, HLA-
C and HLA-E at the mRNA level for all seven donor samples analysed.  We also measured the 
expression of the above HLA types on the differential cell sorts to assess the variability in 
expression across cell types.  ddPCR was performed using the cDNA from PBMC’s and the sorted 
cell types: T-cells (CD3), B-cells (CD19), Monocytes (CD14) and NK cells (CD56).  Primers 
previously designed specifically for each HLA type with high efficiency and specificity were used 





Chapter Four: Results 
4.1 Cell Surface Expression 
The Luminex-LSA bead-based assay was used to screen two Bw4 antibodies against 96 
HLA-I alleles56,57.  The affinities were detected based on the binding of antibody to the respective 
allele and the fluorescence was measured accordingly.  The antibodies, 22E1 (figure 6) and 
REA274 (figure 7), exhibited a broad affinity range for HLA-I alleles and were used to identify 
donors with specific alleles of interest. Common allotypes found within South African 
populations were comprised of 31 HLA-A, 49 HLA-B and 16 HLA-C molecules.  Alleles which 
showed high binding affinities were bound to the antibody with greater strength than those which 
showed lower affinities.  Affinities (blue) are represented on the x-axis and alleles on the y-axis 
in figures 6 and 7.   
Using our sample cohort, we screened for donors from a pool of 300 samples to identify 
specific donors with alleles of interest that were within a 10% variation in antibody affinities.  A 
total of 37 donors were selected to assess the variability in HLA-B allele specific expression using 
the anti-Bw4 antibodies.  Using monoclonal antibody 22E1 (table 2), we obtained a total of 23 
healthy donors which were separated into 2 groups, were each group contained 4 alleles each.  
Alleles selected in 22E1 group 1 were: HLA-B*57:01, HLA-B*49:01, HLA-B*44:02 and HLA-
B*58:01; and group 2: HLA-B*27:05, HLA-B*37:01, HLA-B*38:01 and HLA-B*51:01. 
Grouping of alleles detected using ab 22E1 were represented by purple and green lines in figure 
6, respectively.  Using the REA274 antibody (table 3), we had a total of 5 alleles from 14 donors 
with 3 alleles in one group and 2 alleles in the other.  Alleles selected in REA274 group 1 were:  
group 1: HLA-B*51:01, HLA-B*13:02, and HLA-B*44:03; and group 2: HLA-B*57:01, and 
HLA-B*58:01.   Grouping of alleles detected using ab REA274 were represented by yellow and 






Figure 6: Classification of antibody 22E1 affinity against HLA-I alleles. The affinity of 
anti-Bw4 22E1 used in this study was tested experimentally against 96 of the common HLA-I 
alleles, using LABScreen single antigen-beads coated with donor HLA-I molecules. Grouping of 
alleles detected using ab 22E1 were highlighted in purple (group 1) and green (group 2). 











































































































  REA274 (anti-Bw4) 
 
Figure 7: Classification of antibody REA274 affinity against HLA-I alleles. The affinity of 
anti-Bw4 REA274 used in this study was tested experimentally against 96 of the common HLA-
I alleles, using LABScreen single antigen-beads coated with donor HLA-I molecules.  Grouping 
of alleles detected using ab REA274 were highlighted in yellow (group 1) and red (group 2). 












































































































A single Bw6 allele, obtained from 7 donors, was used as a negative control (data not 
shown) for Ab 22E1 and REA274.    Selected alleles were highlighted in bold print.     
Selection of donors is a critical parameter to consider as if another allele is detected by 
the antibody with a high affinity, the expression of the selected allele is skewed as the other allele 
contributes towards the measured expression.  For example:  if a donor had the following HLA-I 
alleles, with corresponding Ab 22E1 affinity values in brackets – HLA-A*34:02 (66.3), A*23:01 
(13629.7), B*37:01 (13734.8), B*14:02 (55.7), C*01:02 (206.0) and C*12:03 (171.8) – and we 
were interested in determining the expression of B*3701.  Using the affinity graph for antibody 
22E1 (figure 6), this donor would not be appropriate and therefore would not be selected primarily 
due to the affinity of A*23:01 being similar to B*37:01 and therefore, reflecting a combined 
expression of these two alleles.  If A*29:01 was substituted for A*23:01, this donor would be 
selected.  This approached for selection of specific alleles eliminated error for contributing 
expression from another specific allele that may be detected by the respective antibody.   
Samples selected as per tables 2 and 3, were prepared and analysed using flowcytometry 
to establish the corresponding HLA-B cell surface allelic expression.  As previously described, 
alleles were grouped together based on a 10% variation in antibody affinities for Bw4 antibodies 
22E1 and REA274, and expression was quantified for comparison.  Tables 2 and 3 tabulates the 
grouping of alleles based on affinities for antibodies, 22E1 and REA274, respectively.  The 
corresponding HLA-B allele from the selected donors were used to quantify expression, as 










Table 2: Summary of selected HLA-B alleles identified in corresponding donors, based 
on a 10% variation across affinity values of antibody 22E1 obtained from the LSA assay used in 
this study  
Group 1 
PID1 
HLA-B Antibody 22E1 Affinity 
Allele 1 Allele 2 Allele 1 Allele 2 
ID0001 *50:01 *57:01a 5 8148 
ID0002 *07:02 *57:01a 362 8148 
ID0003 *07:02 *58:01a 362 8394 
ID0004 *14:02 *44:02a 56 9110 
ID0005 *35:01 *44:02a 235 9110 
ID0006 *13:02 *44:02 a 85 9110 
ID0007 *07:02 *44:02a 101 9110 
ID0008 *08:01 *44:02a 343 9110 
ID0009 *07:02 *44:02a 101 9110 
ID0010 *08:01 *44:02a 343 9110 
ID0011 *14:02 *44:02a 56 9110 
ID0012 *08:01 *44:02a 343 9110 
ID0013 *15:01 *49:01a 112 10053 
ID0014 *07:02 *49:01a 101 10053 
Group 2 
PID Allele 1 Allele 2 Allele 1 Allele 2 
ID0015 *15:01 *51:01a 112 13161 
ID0016 *08:01 *51:01a 343 13161 
ID0017 *41:01 *51:01a 80 13161 
ID0018 *13:02 *27:05a 85 13561 
ID0019 *15:01 *27:05a 112 13561 
ID0020 *08:01 *27:05a 343 13561 
ID0021 *07:02 *37:01a 101 13735 
ID0022 *35:01 *37:01a 235 13735 
ID0023 *14:01 *38:01a 275 13533 
                                                     
 
 
1 Participant Identity number;  





Table 3: Summary of selected HLA-B alleles identified in corresponding donors, based 
on a 10% variation across affinity values of antibody REA274 obtained from the LSA assay used 




 Participant Identity number;  
a Selected Allele 
Group 1 
PID1 
HLA-B Antibody REA274 Affinity 
Allele 1 Allele 2 Allele 1 Allele 2  
ID0024 *40:02 *44:03a 5 6819 
ID0025 *08:01 *44:03a 3 6819 
ID0026 *08:01 *44:03a 3 6819 
ID0027 *15:01 *44:03a 4 6819 
ID0028 *13:02a *35:01 6337 5 
ID0029 *08:01 *13:02a 3 6337 
ID0030 *07:02 *13:02a 362 6337 
ID0031 *07:02 *13:02a 362 6337 
ID0015 *15:01 *51:01a 4 6600 
ID0016 *08:01 *51:01a 3 6600 
ID0017 *41:01 *51:01a 5 6600 
Group 2 
PID1 Allele 1 Allele 2 Allele 1 Allele 2  
ID0001 *50:01 *57:01a 5 8148 
ID0002 *07:02 *57:01a 362 8148 





Cell surface expression of specific HLA-B alleles (tabulated in Table 2 and 3, 
respectively) were measured using FITC-conjugated antibodies 22E1 and REA274, respectively.  
Selected Bw6 alleles were used as a negative control in the presence of anti-Bw4 antibodies.  
HLA-B cell surface expression is plotted on the y-axis and the HLA-B alleles for each 
22E1/REA274 group is plotted on the x-axis.  HLA-B allelic expression is compared across alleles 
per group.  Variation in HLA-B expression is represented per Ab group in figures 8 and 9, for 
22E1 and REA274 respectively.  Alleles in group 1 of Ab 22E1 show a variability in expression 
across alleles, with HLA-B*57:01 being the highest expressed allele followed by B*49:01, 
B*44:02 and B*58:01, plotted in descending order.  In 22E1 group 2, a similar trend in expression 
was observed with HLA-B*27:05 showing the highest cell surface expression followed by 
B*37:01, B*38:01 and B*5101 in descending order.   
Alleles in group 1 of Ab REA274 also show a variability in expression across HLA-B 
alleles, with HLA-B*51:01 being the highest expressed allele followed by B*13:02, and B*44:03, 
plotted in descending order.  In REA274 group 2, HLA-B*57:01 showed the highest cell surface 
expression followed by B*58:01 in descending order.   A Bw6 alleles was found to have an 
affinity to Ab 22E1 that was below threshold and was therefore used as negative control in group 
































Figure 8: The distribution in expression levels (y-axis) of HLA-B allotypes (x-axis) present 
in healthy HIV- donors.  Peripheral blood CD3+ cells from 23 healthy donors were analysed by 
flow cytometry for HLA-B expression level using the monoclonal antibody 22E1.  An additional 
3 donors with Bw6 alleles were used as a negative control.   MFI of HLA-B staining is plotted 
once for each donor based on the selected allele.  Average expression is expressed by a horizontal 





















































Figure 9: The distribution in expression levels (y-axis) of HLA-B allotypes (x-axis) present 
in healthy HIV- donors.  Peripheral blood CD3+ cells from 14 healthy donors were analysed by 
flowcytometry for HLA-B expression level using the monoclonal antibody REA274.  An 
additional 4 donors with Bw6 alleles were used as a negative control.   MFI of HLA-B staining is 
plotted once for each donor based on the selected allele.  Average expression is expressed by a 





























4.2 mRNA Expression  
4.2.1 HLA Class-I 
Digital droplet PCR was used to measure the mRNA expression of HLA-I types.  Seven 
healthy donors were selected based on sample availability.  RNA extraction and cDNA synthesis 
were performed as previously mentioned.  Samples were prepared for analysis and primers used 
for each HLA type were reported previously in Ramsuran et al., 2017.  The expression of HLA-
A, HLA-B, HLA-C and HLA-E were measured for each donor using PBMC samples and 
graphically illustrated in figure 10 with average HLA-I expression detailed in figure 11.  Each 
donor reports a combination of their allelic expression for each HLA-I type.  Donors 089, 174, 
127, 196, 134, 158, and 187 were each plotted with their corresponding mRNA expression 
(measured in copies per microliter) for each HLA-I type (figure 10).  The concentration was 
plotted on the y-axis and the donors were plotted on the x-axis.  Based on the data demonstrated 
in figure 10, we observed a fluctuation in mRNA expression across donors as well as across HLA 
types.   HLA-B shows a higher concentration in copy numbers across the other HLA-I types.  The 
average mRNA expression (figure 11) displayed a similar trend for HLA-I types, which showed 
that HLA-B had a greater average mRNA expression followed by HLA-A, HLA-C and HLA-E, 

























Figure 10: mRNA expression for HLA-I types across donor samples.  The variation in expression across 7 healthy donor samples (x-axis) for overall 






















































Figure 11: Average mRNA expression levels for HLA-I types across 7 healthy donor 
samples for HLA-A, HLA-B, HLA-C and HLA-E, respectively (x-axis).  mRNA expression is 
reported as the concentration in copies per microliter (µL) (y-axis).  Each donor reports a 
combined expression for each allele across the HLA-I type.  Each donor is plotted 4 times, that 
is, each dot represents the combined mRNA expression per donor for each HLA-I type.  The 
average expression per HLA-I type is denoted by a horizontal black line. 
 
4.2.2 mRNA expression across differential cell types 
PBMC’s of the healthy donors were further sorted into differential cell types using FACS.  
RNA was extracted followed by cDNA synthesis for each cell type: T-cells, B-cells, Monocytes 
and NK cells.  The expression of HLA-A, HLA-B, HLA-C and HLA-E were measured across each 
cell type using ddPCR as previously described.  Figure 12 graphically represents the average 





the y-axis and the differential cell types are plotted on the x-axis for each HLA-I type.   In 
descending order of HLA-I mRNA expression: B-cells, followed by monocytes, and T-cells and 
NK cells at similar levels.  Across each HLA-I type, B-cells showed the highest mRNA expression 
and HLA-B showed the highest expression across cell types.   A similar trend in hierarchy of 
expression across HLA-I types were observed.  Differential expression was observed across cell 
types. 
 
4.2.3 Effect of HIV on HLA-I mRNA expression 
Two donors were selected based on previous data available for pre and post infection 
using PBMC samples.  These donors with identity numbers 284 and 326, were each plotted before 
and after HIV infection to establish an alteration in expression across HLA-A, HLA-B, HLA-C and 
HLA-E, respectively.  mRNA expression for pre- and post- HIV infection is plotted on the y-axis 
and the respective donor samples for each HLA-I type is plotted on the x-axis.  Post- HIV infection 
data show a very slight decrease in mRNA expression in comparison to pre- infection data.  The 
minor decrease in expression is not significant and therefore it can be hypothesised that HIV may 
not downregulate HLA-I at the mRNA level (figure 13) as compared to the cell surface 
expression.  The lack in downregulation of HLA-I by HIV can be further investigated using a 
























Figure 12: Variability in HLA-I mRNA expression across differential cell types.   HLA-A, HLA-B, HLA-C and HLA-E expression (y-axis) measured 
across cell types: PBMC’s, B-cells, T-cells, Monocytes and NK cells (x-axis).  Variability in expression across cell types with B-cells showing the overall 
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Figure 13: Effect of HIV Infection on HLA-I expression levels.  mRNA expression of HLA-I is represented on the y-axis with the corresponding 
donor sample pre- and post- HIV infection on the x-axis.  HIV infection appears to have no significant impact on the regulation of HLA-I types based on 






4.3 Expression comparison 
The alleles measured for cell surface expression, were categorised based on their relative 
antibody affinities, and used to extrapolate the corresponding mRNA expression using expression 
estimates.  The mRNA expression estimates were obtained by averaging the mRNA expression 
data available for a selected allele from previous data and therefore estimating the mRNA 
expression to obtain an average expression estimate.   Expression estimates were thereafter used 
to determine if there was a correlation in mRNA and cell surface expression for a given allele.  
After analysing mRNA and cell surface expression estimates, we observed a trend that 
demonstrated a lack in correlation of estimated mRNA expression and estimated cell surface 
expression at the allelic level per Ab group (figure 14).   
We further attempted to explore the correlation between mRNA expression and cell 
surface expression for each donor per antibody affinity group for each respective antibody.  The 
HLA-B mRNA expression for each donor selected was an estimated average of their respective 
allele and a total average HLA-B mRNA expression estimate was reported.  The mRNA 
expression estimate was compared to the corresponding measured cell surface expression for that 
particular donor.  Correlation data was reported per group per antibody and are illustrated in 
figures 15, 16, 17 and 18, respectively.  There was a lack in correlation of mRNA and cell Surface 
expression levels per donor as selected by monoclonal antibody 22E1 in group 1 (figure 15), 
REA274 group 1 (figure 17) and REA274 group2 (Figure 18).  Presence of a Correlation in 
mRNA and cell Surface expression levels per donor as selected by monoclonal antibody 22E1 in 
group 2.  The correlation observed in this instance was suggestive that expression may be 
regulated at the cell surface for some alleles, however this correlation was only observed at a 
donor level. The average mRNA expression estimates were tested for a correlation in expression 
to the measured cell surface expression obtained from previous analysis using flowcytometry 
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Figure 14: Lack of a correlation in mRNA and cell Surface expression levels at the allelic 
level for several common alleles.   The mRNA expression estimates are plotted on the y-axis and 
the cell surface expression estimates are plotted on the x-axis.  Each dot represents the allelic 
expression estimates calculated for each donor allele measured per antibody group.  The average 
mRNA expression estimates were tested for a correlation in expression to the estimated cell 
surface expression obtained from previous analysis using flowcytometry data, per antibody 
groups for Ab 22E1 (group 1 & 2) and REA274 (group 1).   Correlation in expression for Ab 
REA274 group 2 was not illustrated as only two alleles were measured resulting in insufficient 
data for comparison.   
Correlation of HLA-B allelic expression  
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Figure 15: Lack of correlation in mRNA and cell Surface expression levels per donor as 
selected by monoclonal antibody 22E1 in group 1.  The average mRNA expression estimates were 
tested for a correlation in expression to the measured cell surface expression obtained from 
previous analysis using flowcytometry data.   The mRNA expression estimates are plotted on the 
y-axis and the cell surface expression estimates are plotted on the x-axis. Each dot represents the 
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Figure 16: Presence of a Correlation in mRNA and cell Surface expression levels per donor 
as selected by monoclonal antibody 22E1 in group 2.  The correlation observed in this instance 
was suggestive that expression may be regulated at the cell surface for some alleles, however this 
correlation was only observed at a donor level.  The average mRNA expression estimates were 
tested for a correlation in expression to the measured cell surface expression obtained from 
previous analysis using flowcytometry data.   The mRNA expression estimates are plotted on the 
y-axis and the cell surface expression estimates are plotted on the x-axis. Each dot represents the 
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Figure 17: Lack of correlation in mRNA and cell Surface expression levels per donor as 
selected by monoclonal antibody REA274 in group 1.  The average mRNA expression estimates 
were tested for a correlation in expression to the measured cell surface expression obtained from 
previous analysis using flowcytometry data.   The mRNA expression estimates are plotted on the 
y-axis and the cell surface expression estimates are plotted on the x-axis. Each dot represents the 
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Figure 18: Lack of correlation in mRNA and cell Surface expression levels per donor as 
selected by monoclonal antibody REA274 in group 2.  The average mRNA expression estimates 
were tested for a correlation in expression to the measured cell surface expression obtained from 
previous analysis using flowcytometry data.   The mRNA expression estimates are plotted on the 
y-axis and the cell surface expression estimates are plotted on the x-axis. Each dot represents the 










Chapter Five: Discussion 
 
5.1 HLA-I diversity and Antibody Selection 
The HLA region is the most polymorphic region in the human genome, listing HLA as 
being diversely associated with a broad range of diseases5,23,24,26–28,36,49.  Some of the diversity in 
HLA’s arises from their ability to present a wide array of peptides, similarity in nucleotide 
sequences yet variability in their promoter regions and complexity in mechanistic regulation of 
expression and variation in expression across alleles.   HLA-I alleles have been shown to play a 
major role in immune mediated control of HIV infection4, and several studies have associated 
HLA expression with HIV disease outcomes14,34,35,42,43.   Elevated expression of HLA-C was 
found to reduce progression of HIV whereas elevated HLA-A expression resulted in the converse 
of HLA-C35,42.   It was also observed that the expression was variable across alleles, with some 
alleles being expressed at higher levels than others.  Several HLA-B alleles, such as HLA-B*57, 
HLA-B*27, HLA-B*5, have been extensively studied, due to their association with HIV.  HLA-
B is also the most polymorphic region within the human genome with over 5,500 known alleles, 
more than HLA-A and HLA-C61.   However, not much is known about expression across HLA-
B alleles or the variability across cell types.    
 
This study bridged the lack in knowledge across HLA-B expression and discovered great 
insight into the expression of HLA-I at the cell surface and mRNA levels.  Literature emphasizes 
that the production and characterization of monoclonal antibodies against HLA molecules makes 
it possible to analyse HLA expression in human cells62.  Critical factors to consider when 
measuring allelic variations in HLA-I cell surface expression are the: (a) the specificities of the 
antibodies that are used for the quantification of expression, and (b) the differences in the binding 






Prior to measuring the cell surface expression, commercially available Bw4 antibodies, 
22E1 and REA274, were required to be screened against a range of HLA alleles to assess affinity, 
that is, the strength to which an antibody binds to an allele.  HLA-C allelic expression was easily 
measured in a previous study, using DT9 as the antibody of choice34.  DT9 binds to HLA-C alleles 
with equal affinity and can therefore measure the expression across all HLA-C alleles for 
comparison.  This was not the case with HLA-B alleles.  Using the Luminex-LSA assay, two 
BW4 antibodies were selected and used in analysis of HLA-B variation in cell surface expression.    
Donors within a 10% variability in antibody affinity of each other were selected and used to assess 
the variability in allele specific expression at the cell surface. 
 
5.2 HLA Expression 
HLA-B alleles were selected based on antibody affinity and presence of alleles within the 
sample cohort.  Selected alleles were tabulated in tables 2 and 3, respectively.  HLA-B allele-
specific expression was measured using flowcytometry.  A FITC conjugated monoclonal 
antibody, that is, 22E1 or REA27, was used to quantify the surface expression of selected HLA-
B alleles.  Expression of alleles in group 1: HLA-B*5701, HLA-B*4901, HLA-B*4402 and HLA-
B*5801; and group 2: HLA-B*2705, HLA-B*3701, HLA-B*3801 and HLA-B*5101 are shown 
in figure 8 and were within a 10% variation in antibody affinity of each other per group.   In each 
group, we observed a variation in expression across HLA-B alleles measured with antibody 22E1.  
In figure 9, a similar trend across HLA-B alleles measured with antibody REA274 was observed.  
Expression of alleles in group 1: HLA-B*5101, HLA-B*1302, and HLA-B*4403; and group 2: 
HLA-B*5701, and HLA-B*5801 are shown in figure 9 and were within a 10% variation in 
antibody affinity of each other per group.   Based on the alleles selected and antibodies used, we 
can conclude that some antibodies have a greater specificity for some alleles than others and hence 
antibody selection is a critical factor in quantifying cell surface expression.  In contrast to other 





and antibody used, HLA-B*57:01 has an overall higher cell surface expression in comparison to 
HLA-B*58:01 from an allele specific level.  However, this observation can be further examined 
by increasing the number of alleles to assess hierarchy in allelic specific expression at the cell 
surface. 
 
   Interestingly, the only one other study that assessed HLA-B expression at the mRNA 
levels, observed a lack in variation across donors and no HLA-B allele-specific mRNA expression 
variation23.  The trend observed for the dissimilarity of allelic expression was also supported by 
a previous study that attributed allele variations due to antigen acquisition pathways having an 
influence on HLA-B surface expression levels65.   Other similar studies suggest that cell surface 
expression levels of HLA-B does vary in a lineage-specific manner to a degree, and this may be 
attributed to result from lineage-specific  translational events63,64. The findings in this study 
further substantiates that other mechanisms drive the expression of HLA-B post transcriptional, 
as discussed by Yarzabek et al, 2018; and that there is no correlation in cell surface and mRNA 
expression levels23,65.  Quantifying HLA-I cell surface expression variability is also antibody 
specific as well as on the cell type measured.  As demonstrated in a study that used three selective 
antibodies (Tu149, B1.23.2, and 22E1), it was found that the expression of HLA-B alleles (in 
ascending order of expression): HLA-B*35, HLA-B*07, HLA-B*27, and HLA-B*57 were 
inversely correlated with the promiscuity of peptide binding63.  However, in another study that 
examined the surface expression of HLA-B*57 and HLA-B27 using a different antibody, clone 
0007, it was found that HLA-B*27 had higher expression than HLA-B*5764.  Ramsuran et al., 
2017 attributed these differences in measurement to the use of different cell types in the respective 
studies, therefore supporting that some cell types express HLA-I at different expression 
levels23,63,64.  Dependent on the HLA type, it can be observed that higher expressed alleles tend to 
have lower peptide promiscuity and lower expressed alleles have higher peptide promiscuity, and 
to some extent, HLA-B expression varies in a lineage specific manner23,63.  However, the data that 





affinity for specific alleles and therefore antibody selection is a critical factor that must be 
considered when measuring HLA cell surface expression.  It is also critical to perform a titration 
of the antibody selected for use in order to establish the correct concentration and quantity of 
antibody that is acceptable for use when measuring cell surface expression using the LSA assay.  
Previous studies that have measured expression of HLA-I without establishing an effective 
antibody concentration and based on the previously reported data, the expression measured for 
specific alleles using the selected antibody was not comparable to other reported data and 
therefore not accurately reproducible63,66,67.  It is proposed to further explore a larger selection of 
alleles using a single antibody and group, as well as across different ethnicities, to establish a 
possible hierarchy in HLA-B allelic cell surface expression.   
 
The mRNA expression across donors for each HLA-I type: HLA-A, HLA-B, HLA-C and 
HLA-E were found to be variable across types.  The seven donors selected showed consistency in 
variability across donors as well as across HLA types.  Using ddPCR, samples were partitioned 
in to ~20,000 droplets and amplified using highly specific primers used in a previous study23.   
Concentration of positive target sequences were reported in copies per microliter for all ddPCR 
analysis graphs.  Data reported in this study observed a fluctuation in mRNA expression across 
the donors.  Overall, we observed a higher concentration of HLA-B across the donors in 
comparison to the other HLA-I types.  This trend in expression was also detected in the average 
mRNA expression reported for HLA-I types, which showed that HLA-B had a greater expression 
across class-I HLA genes, followed by HLA-A, HLA-C and HLA-E in descending order.  This 
trend in mRNA expression follows that reported by Apps et al., 2013 for cell surface expression 
for HLA-I types42.  However, it has also been reported that there is no correlation in mRNA and 
cell surface expression as observed with HLA-C34,42,43. 
 
Ramsuran et al., 2017 reported for the first time HLA-B allelic mRNA expression using 





comprising PBMC’s, variation in expression observed in the lower population cell subtypes will 
not be detected.  We therefore attempted to repeat that experiment across cell types to determine 
if HLA-I expression varies across differential cell types.  Using FACS, a technique based on the 
principle of flowcytometry, we sorted the PBMC samples into T-cells, B-cells, Monocytes and 
Natural Killer Cells.  Samples were prepared and analysed as previously described.  The mRNA 
expression was graphically illustrated in figure 12.  Expression was plotted for PBMC samples, 
T-Cells, B-cells, Monocytes and NK cells for each of the class-I types: HLA-A, HLA-B, HLA-C 
and HLA-E.  As previously observed, expression levels measured using PBMC’s shows a lack in 
variability across HLA-I types23, however, across cell types, a distinct variation can be observed.   
Across the HLA-I types, a trend highlighting increased mRNA expression in B-cells, followed by 
monocytes, and similar expression observed in T-cells and NK cells.  Interestingly, it was also 
observed that HLA-B mRNA expression is predominately higher than the other HLA-I types.  
This trend in HLA-I expression was also supported by figures 10 and 11, as previously mentioned.   
 
It is known that HIV protein, Nef, downregulates HLA-A and B at the cell surface, 
however with different efficiencies14,50,51.  However, it is unknown if this downregulation, if any, 
is also observed at the mRNA level.  We attempted to further investigate the possible 
downregulation on pre- and post- HIV infected cells for the same donors.  Two donors were 
identified from the CAPRISA 002 cohort and samples were obtained before and after HIV 
infection.  mRNA expression of HLA-A, HLA-B, HLA-C and HLA-E was measured for each donor 
at the two time points.  Figure 13 graphically illustrates the mRNA expression measured pre- and 
post- HIV infection.  Post infection expression demonstrates a slight reduction in expression in 
comparison to pre- infection expression of HLA-A, HLA-B, HLA-C and HLA-E.  Nevertheless, 
the reduction was insignificant and therefore, it can be assumed that in contrast to cell surface 







5.3 Comparison of Expression in HLA-I 
It was previously reported that there is no correlation in mRNA and cell surface 
expression however based on the similarity of trends observed in the hierarchy of HLA-I 
expression as observed in figure 11, and reports by Apps et al., 201514,65, we attempted to explore 
a possible correlation of mRNA and cell surface expression across donors as well as across alleles.  
Based on the average expression estimates obtained for specific alleles (figure 14), there was a 
lack of correlation in mRNA and cell Surface expression levels at the allelic level for each group 
of selected alleles.  Alleles were grouped based on antibody affinity values as determined in 4.1.  
We further attempted to identify a correlation in expression at a donor level for each group of 
alleles selected per antibody.  In figures 15, 17 and 18, no significant correlation in expression 
was observed at the donor level.  Interestingly, a correlation in mRNA and cell surface expression 
level was observed in donors selected by monoclonal antibody 22E1 in group 2 (figure 16).  The 
correlation observed in this instance was suggestive that expression may be differentially 
regulated at the cell surface for some alleles, however this correlation was only observed at a 
donor level and not allelic level and should therefore be analysed with careful consideration.  It 
is possible, if explored with a larger selection of alleles using a single antibody and group, as well 
as across different ethnicities, that a stronger correlation may also be established for specific 






Chapter Six: Conclusion 
 
Human Leukocyte Antigens are specialised molecules that directly links the hosts immune 
system with the internal environment within every nucleated cell.  Aside from such linkage, these 
molecules play a pivotal role in diseases and up until recently have been associated with disease 
outcomes.  Several HLA-B alleles have been extensively studied and associations have led to the 
discovery of protective and unfavourable alleles.  Published literature has to date, reported the 
outcome of HIV disease in association with expression of HLA-A and HLA-C.  Although several 
genome wide association studies have reported HLA-B to have the strongest disease associations, 
limited information exists for HLA-B expression.  With HLA-B being the most polymorphic 
region within the human genome, we decided to fill some gaps in knowledge surrounding HLA-
B expression.  In this study, we have determined that HLA-B expression is variable across alleles 
at the cell surface, however antibody and allele selection prior to measuring cell surface 
expression are critical aspects that require a thorough understanding and attention to detail.  As 
previously described, HLA-B expression at the mRNA level was found to be stable across alleles 
in comparison HLA-A and HLA-C.  Since the study was conducted using PBMC’s to quantify 
variability in expression across alleles, we were posed with the theory that expression varied 
across cell types.  Interesting, across HLA-I types, we observed that B-cells have an overall higher 
expression across cell types and HLA-B had an overall higher expression across HLA-I types.  
We also found that the expression of HLA-I types was not downregulated at the mRNA level as 
observed on the cell surface level in the presence of HIV.   Based on analysis of expression data, 
we observed that there was no correlation in mRNA and cell surface expression.  In contrast, we 
also observed that some alleles may be differently regulated at the cell surface, however this 
correlation was found at the donor level and not across the alleles.  Notable limitations of the 
study were that not all HLA-B alleles were assessed for variability in expression, and greater 
power can be achieved if the comparison was performed using multiple cohorts of various 





Analysis of HLA-B expression level is likely to be important not only in HIV infection, but 
also other infectious diseases and immune-related disorders in which HLA-B is implicated.   HLA 
expression levels adds another dimension to the extreme diversity of HLA-I molecules that 
accounts for variability in immune responses across donors and may suggest possible drug targets 
to modulate host responses to infections.  Further insight into the factors that may be involved in 
the regulation of HLA-B at the genomic level could provide valuable information in understanding 
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